Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 341

1.

Nodular lymphocyte predominant Hodgkin lymphoma.

Lee AI, LaCasce AS.

Oncologist. 2009 Jul;14(7):739-51. doi: 10.1634/theoncologist.2009-0099. Epub 2009 Jul 15. Review.

2.

Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma.

Boudová L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S, Diehl V, Müller-Hermelink HK, Rüdiger T.

Blood. 2003 Nov 15;102(10):3753-8. Epub 2003 Jul 24.

3.

European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes.

Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, Diehl V, Stein H.

Blood. 2000 Sep 1;96(5):1889-99.

4.

Nodular lymphocyte-predominant hodgkin lymphoma with atypical T cells: a morphologic variant mimicking peripheral T-cell lymphoma.

Sohani AR, Jaffe ES, Harris NL, Ferry JA, Pittaluga S, Hasserjian RP.

Am J Surg Pathol. 2011 Nov;35(11):1666-78. doi: 10.1097/PAS.0b013e31822832de.

PMID:
21997687
5.

Nodular lymphocyte-predominant hodgkin lymphoma.

Tsai HK, Mauch PM.

Semin Radiat Oncol. 2007 Jul;17(3):184-9. Review.

PMID:
17591565
6.

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Skinnider BF, Elia AJ, Gascoyne RD, Trümper LH, von Bonin F, Kapp U, Patterson B, Snow BE, Mak TW.

Blood. 2001 Jan 1;97(1):250-5.

7.

The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.

Maeda LS, Advani RH.

Curr Opin Oncol. 2009 Sep;21(5):397-400. doi: 10.1097/CCO.0b013e32832f3ca3. Review.

PMID:
19606035
8.

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG).

Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M.

Blood. 2008 Jan 1;111(1):109-11. Epub 2007 Oct 15.

9.

Nodular lymphocyte predominant Hodgkin's lymphoma.

Siddiqui N, Al-Diab AI.

Saudi Med J. 2005 Feb;26(2):241-5.

PMID:
15770298
10.

Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.

Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA.

Am J Surg Pathol. 2003 Oct;27(10):1346-56.

PMID:
14508396
11.

Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.

Drakos E, Rassidakis GZ, Leventaki V, Cotta CV, Vega F, Medeiros LJ.

Am J Surg Pathol. 2009 Nov;33(11):1725-31. doi: 10.1097/PAS.0b013e3181b27765.

PMID:
19730363
13.

Comparative flow immunophenotypic features of the inflammatory infiltrates of Hodgkin lymphoma and lymphoid hyperplasia.

Hudnall SD, Betancourt E, Barnhart E, Patel J.

Cytometry B Clin Cytom. 2008 Jan;74(1):1-8.

14.
15.

[Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis].

Carbonnelle A, Delarue R, Canioni D, Brousse N.

Ann Pathol. 2004 Apr;24(2):136-48; quiz 135. Review. French.

PMID:
15220833
16.

PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma.

Nam-Cha SH, Roncador G, Sanchez-Verde L, Montes-Moreno S, Acevedo A, Domínguez-Franjo P, Piris MA.

Am J Surg Pathol. 2008 Aug;32(8):1252-7. doi: 10.1097/PAS.0b013e318165b0d6.

PMID:
18594468
17.

Immunoprofile of Hodgkin's lymphoma in India.

Patkar N, Mehta J, Kulkarni B, Pande R, Advani S, Borges A.

Indian J Cancer. 2008 Apr-Jun;45(2):59-63.

18.

Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.

Farrell K, McKay P, Leach M.

Leuk Lymphoma. 2011 Oct;52(10):1920-8. doi: 10.3109/10428194.2011.584993. Epub 2011 Jun 12.

PMID:
21663507
19.

Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.

Muenst S, Hoeller S, Dirnhofer S, Tzankov A.

Hum Pathol. 2009 Dec;40(12):1715-22. doi: 10.1016/j.humpath.2009.03.025. Epub 2009 Aug 19.

PMID:
19695683
20.

Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma.

Rahemtullah A, Harris NL, Dorn ME, Preffer FI, Hasserjian RP.

Leuk Lymphoma. 2008 Oct;49(10):1870-8. doi: 10.1080/10428190802308728. Review.

PMID:
18949610

Supplemental Content

Support Center